Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method

BACKGROUND: HER2/Neu (ErbB-2) overexpression, which occurs in 15–20% of breast cancer cases, is associated with better response to treatment with the drug trastuzumab. PhosphoHER2 (pHER2) has been evaluated for prediction of response to trastuzumab. Both markers are heterogeneously detected and are...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Yalai, Cheng, Huan, Bordeaux, Jennifer, Neumeister, Veronique, Kumar, Sudha, Rimm, David L., Stern, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836903/
https://www.ncbi.nlm.nih.gov/pubmed/24278211
http://dx.doi.org/10.1371/journal.pone.0079901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836903/
https://www.ncbi.nlm.nih.gov/pubmed/24278211
http://dx.doi.org/10.1371/journal.pone.0079901

Ejemplares similares